Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors

Authors

Kevin Conlon, National Cancer Institute, Bethesda
Andrea Wang-Gillam, Washington University School of Medicine in St. Louis
et al

Journal

Journal for Immunotherapy of Cancer

Publication Date

11-1-2021

Volume

9

Issue

11

First Page

e003388

Document Type

Open Access Publication

DOI

10.1136/jitc-2021-003388

Rights and Permissions

Conlon K, Watson DC, Waldmann TA, et alPhase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumorsJournal for ImmunoTherapy of Cancer 2021;9:e003388. doi: 10.1136/jitc-2021-003388. https://jitc.bmj.com/content/9/11/e003388 Copyright 2021 The Authors This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.

Recommended Citation

Conlon, Kevin; Wang-Gillam, Andrea; and et al, "Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors." Journal for Immunotherapy of Cancer. 9, 11. e003388 (2021).
https://digitalcommons.wustl.edu/oa_4/116